브래디키닌 수용체 B1(B1)은 인간의 BDKRB1유전자에 의해 인코딩된 G단백 결합 수용체다.주된 리간드는 염증, 외상, 화상, 충격, 알레르기 등 병태생리학적 조건에서 생성되는 9개의 아미노산 펩타이드인 브래디키닌이다.B1 수용체는 브래디키닌을 결합하고 이러한 병리학적 조건에 대한 반응을 중재하는 G 단백질 결합 수용체 중 두 개 중 하나이다.
B단백질은1 조직손상 후 노보 합성되며 수용체 결합은 세포질 칼슘 이온 농도의 증가로 이어져 궁극적으로 만성 및 급성 염증 반응을 일으킨다.[5]
이 수용체의 고전 작용제는 브라디키닌1-8(최초 8아미노산을 함유한 브라디키닌)을 포함하고, 길항제에는 [Leu8]-브라디키닌1-8을 포함한다.[6]
Yang X, Polgar P (1996). "Genomic structure of the human bradykinin B1 receptor gene and preliminary characterization of its regulatory regions". Biochem. Biophys. Res. Commun. 222 (3): 718–25. doi:10.1006/bbrc.1996.0810. PMID8651911.
Bachvarov DR, Hess JF, Menke JG, et al. (1996). "Structure and genomic organization of the human B1 receptor gene for kinins (BDKRB1)". Genomics. 33 (3): 374–81. doi:10.1006/geno.1996.0213. PMID8660997.
Chai KX, Ni A, Wang D, et al. (1996). "Genomic DNA sequence, expression, and chromosomal localization of the human B1 bradykinin receptor gene BDKRB1". Genomics. 31 (1): 51–7. doi:10.1006/geno.1996.0008. PMID8808279.
Blaukat A, Herzer K, Schroeder C, et al. (1999). "Overexpression and functional characterization of kinin receptors reveal subtype-specific phosphorylation". Biochemistry. 38 (4): 1300–9. doi:10.1021/bi981727r. PMID9930991.
Cassano G, Susca F, Lippe C, Guanti G (1999). "Two B1 and B2 bradykinin receptor antagonists fail to inhibit the Ca2+ response elicited by bradykinin in human skin fibroblasts". Gen. Pharmacol. 32 (2): 239–44. doi:10.1016/S0306-3623(98)00275-4. PMID10188626.
Zhou X, Prado GN, Chai M, et al. (2000). "Posttranscriptional destabilization of the bradykinin B1 receptor messenger RNA: cloning and functional characterization of the 3'-untranslated region". Mol. Cell Biol. Res. Commun. 1 (1): 29–35. doi:10.1006/mcbr.1999.0105. PMID10329474.
Jones C, Phillips E, Davis C, et al. (1999). "Molecular characterisation of cloned bradykinin B1 receptors from rat and human". Eur. J. Pharmacol. 374 (3): 423–33. doi:10.1016/S0014-2999(99)00315-5. PMID10422787.
Sjuve R, Boels PJ, Uvelius B, Arner A (2000). "Up-regulation of bradykinin response in rat and human bladder smooth muscle". J. Urol. 164 (5): 1757–63. doi:10.1016/S0022-5347(05)67102-9. PMID11025765.
Sawant S, Snyman C, Bhoola K (2002). "Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms". Int. Immunopharmacol. 1 (12): 2063–80. doi:10.1016/S1567-5769(01)00118-7. PMID11710536.
Newton R, Eddleston J, Haddad el-B, et al. (2002). "Regulation of kinin receptors in airway epithelial cells by inflammatory cytokines and dexamethasone". Eur. J. Pharmacol. 441 (3): 193–202. doi:10.1016/S0014-2999(01)01624-7. PMID12063092.
Kang DS, Leeb-Lundberg LM (2002). "Negative and positive regulatory epitopes in the C-terminal domains of the human B1 and B2 bradykinin receptor subtypes determine receptor coupling efficacy to G(q/11)-mediated [correction of G(9/11)-mediated] phospholipase Cbeta activity". Mol. Pharmacol. 62 (2): 281–8. doi:10.1124/mol.62.2.281. PMID12130679.
Lamb ME, Zhang C, Shea T, et al. (2003). "Human B1 and B2 bradykinin receptors and their agonists target caveolae-related lipid rafts to different degrees in HEK293 cells". Biochemistry. 41 (48): 14340–7. doi:10.1021/bi020231d. PMID12450400.